Allogene Therapeutics investor relations material

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It is developing UCART19, an investigational chimeric antigen receptor T cell product candidate for the treatment of CD19 expressing hematological malignancies; and ALLO-501, an investigational alloCAR T product candidate for the treatment of B-cell non-Hodgkin lymphoma. The company was formerly known as Allogen BioPharma, Inc. and changed its name to Allogene Therapeutics, Inc. in June 2018. Allogene Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.